Loading
Every dated change on the records linked to Astrocytoma, IDH-mutant (grades 2 to 4), newest first: approvals and regulatory steps on its medicines, trials that reported, guideline versions, milestones, and when this page itself was checked. Dates come from the records; none is inferred. Orientation, not medical advice.
Median progression-free survival 46 (radiotherapy) vs 39 months (temozolomide), no significant difference.
Buckner and colleagues (NEJM) report median overall survival of 13.3 years against 7.8 years with radiotherapy alone.
A milestone in how this cancer is treated.